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Objective: To evaluate the effects on the nutritional and metabolic parameters of a very-low-protein diet supplemented with
ketoacids (VLPDþKA) in comparison with a conventional low-protein diet (LPD) in chronic kidney disease (CKD) patients.
Design: Prospective, randomized, controlled clinical study.
Setting: Outpatient Clinic of the Nephrology Division of Federal University of Sa˜o Paulo, Brazil.
Subjects: The study involved 24 patients with advanced CKD (creatinine clearance o25 ml/min) that were randomly assigned
to either a VLPDþKA (VLPDþKA group, 12 patients) or to a conventional LPD with 0.6 g/kg/day (LPD group, 12 patients). The
patients were followed for 4 months.
Results: Nutritional status was adequately maintained with both diets for the studied period. Protein intake and serum urea
nitrogen decreased significantly only in the VLPDþKA group (from 0.6870.17 to 0.4370.12 g/kg/day, Po0.05; from
61.4712.8 to 43.6714.9 mg/dl, Po0.001; respectively). Ionized calcium did not change in the VLPDþKA group but tended to
decrease in the LPD group. Serum phosphorus tended to decrease in the VLPDþKA group probably as a result of a significant
reduction in dietary phosphorus (5297109 to 3737125 mg/day, Po0.05) associated to the phosphorus-binding effect of the
ketoacids. No change in these parameters was found in the LPD group. Serum parathormone increased significantly only in the
LPD group (from 2417138 to 4947390 pg/ml, Po0.01). The change in PTH concentration was negatively correlated with
changes in ionized calcium concentration (r¼0.75, P¼ 0.02) and positively correlated with changes in serum phosphorus
(r¼ 0.71, P¼0.03) only in the LPD group.
Conclusion: This study indicates that a VLPDþKA can maintain the nutritional status of the patients similarly to a conventional
LPD. Besides, an improvement in calcium and phosphorus metabolism and a reduction in serum urea nitrogen were attained
only with the VLPDþKA. Thus, VLPDþKA can constitute another efficient therapeutic alternative in the treatment of CKD
patients.
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Introduction
Dietary intervention is one of the major components of
chronic kidney disease (CKD) patients therapy and aims to
minimize uremic symptoms and to provide optimum
nutritional status. In order to limit the accumulation of
nitrogenous waste products, and in the hope of slowing the
progression of renal failure, dietary protein restriction has
been recommended for patients with moderate to severe
CKD (Mitch, 2002).
Various dietary regimens have been proposed: a conven-
tional low-protein diet (LPD) providing 0.6 g protein/kg/day
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or a very-low-protein diet (VLPD) providing 0.3 g/kg/day
supplemented with essential amino acids (EAA) or a mixture
of essential amino acids and ketoacids (KA). Both diets
reduce nitrogen intake while providing the physiological
requirement of essential amino acids.
Many authors have demonstrated that VLPDþKA has
favorable effects on various metabolic consequences of
uremia, including metabolic acidosis (Chauveau et al, 1999;
Aparicio et al, 2000), secondary hyperparathyroidism (Lin-
denau et al, 1990; Lafage et al, 1992; Barsotti et al, 1998),
peripheral resistance to insulin (Gin et al, 1987; Rigalleau et al,
1997) and hyperlipidemia (Ciardella et al, 1986; Bernard et al,
1996). The correction of many such adverse effects of uremia
by VLPD may be useful to delay the start of renal replacement
therapy in patients with advanced CKD (Walser & Hill, 1999).
Although concern has been raised about the nutritional
adequacy of these diets and the risk for the subsequent
development of malnutrition (Aparicio et al, 2001) studies
have demonstrated that a VLPDþKA in carefully selected
and motivated patients with advanced CKD has no deleter-
ious influence on some nutritional parameters in the
predialysis phase of CKD (Mitch et al, 1982; Walser, 1993;
Masud et al, 1994; Tom et al, 1995; Aparicio et al, 2001).
However, only a few studies have included a control group
and patients that were previously following a conventional
low protein diet.
The present study aimed to evaluate the effects on the
nutritional and metabolic parameters of a VLPD supplemen-
ted with ketoacids in comparison with a conventional LPD
in advanced CKD patients.
Subjects and methods
Patients
The study was performed with CKD patients treated at the
outpatient clinic of Nephrology Division, Federal University
of Sa˜o Paulo—UNIFESP and Oswaldo Ramos Foundation. A
total of 24 patients were selected after satisfying the
following clinical inclusion criteria: creatinine clearance
r25 ml/min/1.73 m2, older than 18 y, absence of catabolic
illnesses, diabetes mellitus, auto-immune disease and malig-
nant hypertension.
The study was approved by the Human Investigation
Review Committee of the Federal University of Sa˜o Paulo—
UNIFESP and informed consent was obtained from each
patient.
Study protocol
A prospective, randomized, controlled clinical study was
performed. After meeting the inclusion criteria and provid-
ing informed written consent, all patients were instructed to
eat a low protein diet (0.6 g/kg ideal body weight/day) for a
period of at least 1 month. After this period, the patients
were randomly assigned to either a VLPD supplemented with
a mixture of ketoacids and amino acids (VLPDþKA group)
or to keep the previous prescribed LPD (LPD group).
The patients were studied for a 4-month period. Once a
month, the patients met with the dietitian and the physician
for a complete clinical and biochemical evaluation and for
encouragement and verification of compliance, safety and
efficacy of the dietary prescription. At 2-monthly intervals, a
complete nutritional assessment was performed.
The study protocol is depicted in Figure 1.
Diet
The patients were carefully instructed by a skilled dietitian
for the corresponding diet. The LPD diet consisted of 0.6 g/
kg/day of protein (50% of high biological value). Patients
assigned to VLPDþKA group were prescribed a 0.3 g/kg/day
of vegetal origin protein diet supplemented with a mixture
M = month 
* Complete nutritional assessment. 
** Clinical and biochemical evaluation. 
VLPD+KA group
LPD group 
1 month 
baseline *       1 M**      2 M*      3 M**       4 M*
randomization 
protein 0.6 g/kg/d 
(LPD) 
Figure 1 Schematic diagram of the study protocol.
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of ketoacids and amino acids (Ketosterils, Fresenius Kabi,
Ltda, Bad Homburg, Germany). The ketoacid prescription
consisted of one tablet/5 kg ideal body weight/day, divided
into three doses taken during meals. The composition of the
tablets is described in Table 1. For both groups, energy
prescription was 126–146 kJ/kg ideal body weight/day (30–
35 kcal/kg ideal body weight/d). All patients were given
supplements of vitamin B and iron and phosphate binders
were prescribed when necessary.
Nutritional assessment
Dietary assessment. Energy and nutrient intake were
estimated from a 3-day food diary (3 week days), using a
computer software developed at UNIFESP and the United
States of America Department of Agriculture (1963) table as
the nutrient data base. Protein intake was also estimated
from the normalized protein equivalent of nitrogen appear-
ance (nPNA), determined according to the formula of
Sargent and Gotch (1979) using 24-h urinary urea excretion.
Anthropometric data and body composition. The follow-
ing anthropometric parameters were evaluated: body weight,
height, midarm circumference and triceps skinfold thickness
(TSF). Body mass index (BMI) was calculated as body weight
divided by squared height. The cutoff points used were as
recommended by WHO—World Health Organization (1995).
Ideal body weight was obtained from the Metropolitan Life
Insurance tables. The TSF was measured to the nearest
millimeter using a Langes skinfold caliper (Cambridge
Instrument, Cambridge, MD, USA) and three sets of
measurements were averaged. Midarm-muscle circumference
(MAMC) was calculated from the measurement of midarm
circumference and triceps skinfold thickness. The measure-
ments were performed on the nondominant side of the body.
Percent standard of TSF and MAMC were obtained using the
National Health and Nutrition Examination Survey
(NHANES) percentile distribution tables adapted by Frisan-
cho (1981).
Body composition was evaluated using bioelectrical im-
pedance analysis (BIA) that was performed using a single
frequency tetrapolar technique (800 A, 50 kHz, BIA 101
Quantum, RJL Systems, Detroit, MI, USA). The software
Fluids & Nutrition (version 3.0) provided by the manufac-
turer was used to estimate the body composition.
Biochemical data. The patients had blood drawn under
fasting conditions. The following biochemical data were
measured on a monthly basis: serum and urinary urea and
phosphorus, serum creatinine, ionized calcium, and bicar-
bonate. A 24-hour urine collection was obtained to measure
protein excretion and to estimate glomerular filtration rate
using standard creatinine clearance corrected for the body
surface area (1.73 m2).
At 2-month intervals, two additional biochemical data
were determined: albumin (bromocresol green technique,
normal range 3.4–4.8 g/dl) and intact parathyroid hormone
(immunofluorometric assay, normal values 10–70 pg/ml).
Statistical analysis
All data are expressed as mean7standard deviation (s.d.).
The statistical analysis was performed considering three
periods, baseline, 2 months and 4 months for anthropo-
metric and dietary parameters and two periods, baseline and
4 months for biochemical parameters. Analysis of variance
(ANOVA) complemented with Bonferroni test was employed
for comparisons of anthropometric and dietary parameters
from the three periods. Fisher’s exact test was used for
comparisons between groups, as applicable. Paired Student’s
t-test was used to compare the biochemical parameters
between baseline and 4 months. The differences between
the two periods comparing the two groups were analyzed
using independent Student’s t-test. Pearson’s correlation
coefficient was calculated to test quantitative associations
between two variables. Statistical significance was defined as
Po0.05. The software used for statistical analysis was True
Epistat (Epistat Services, Richardson, TX, USA).
Results
Demographic and clinical characteristics of the patients at
baseline are presented in Table 2. There was a predominance
of males in both groups and there was no difference in terms
of age between them. Serum creatinine, urea nitrogen and
urinary protein were similar in the two groups. According to
the creatinine clearance the majority of patients (75%) were
in stage 4 CKD. Hypertensive nephrosclerosis was the cause
of CKD in seven patients in the VLPDþKA group and in
three patients in the LPD group while chronic glomerulone-
phritis was the cause of CKD in three patients only in the
LPD group. Chronic interstitial nephritis was the etiology of
CKD in one patient in the VLPDþKA group and in two of
them in the LPD group. Three patients and one patient of
each group had undetermined and other causes of CKD,
respectively. In total, 96% of the studied patients were taking
furosemide as a diuretic. Antihypertensive medications were
Table 1 Chemical composition of ketoacid–amino-acid supplement per
tablet (mg)
Ca-DL-3-methyl-2-oxo-valerianate 67
Ca-4-methyl-2oxo-valerianate 101
Ca-2-oxo-3-phenyl-propionate 68
Ca-3-methyl-2-oxo-butyrate 86
Ca-DL-2-hydroxy-4-methylthio-butyrate 59
L-Lysinmonoacetate 105
L-Threonine 53
L-Tryptophan 23
L-Histidine 38
L-Tyrosine 30
Total-N/tablet 36
Total-calcium/tablet 50
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prescribed for 92% of them. Angiotensin-converting enzyme
inhibitors were prescribed for four patients in the VLPDþKA
group and five patients in the LPD group. During the study
four patients required calcium carbonate as a phosphate
binder (one VLPDþKA group, three LPD group) and 11
required iron supplementation (seven VLPDþKA group,
four LPD group).
Analysis of follow-up
Table 3 shows the anthropometric and dietary parameters of
the two groups during the follow-up. At baseline, 50% of the
patients in both groups presented a body mass index
between 18.5 and 24.9 kg/m2 and 50% of them were
overweight (BMI 425 kg/m2). As can be seen, BMI did not
change in either group during the follow-up. Percent of body
fat of the female and male patients at baseline was 34.079.6
and 17.673.1%, respectively, in the VLPDþKA group, while
in the LPD group it was 40.274.6 and 18.475.3%,
respectively. In both groups, percent of body fat remained
constant during the study. The mean standard percent of TSF
and MAMC at baseline was within the normal range in both
groups and did not change during the study in the
VLPDþKA group, while in the LPD group, the mean
standard percent of TSF increased significantly but remained
in the normal range. Lean body mass did not change during
the follow-up in both groups.
Protein intake estimated by dietary diaries at baseline was
according to the amount previously prescribed (0.6 g/kg/day)
in both groups and as expected decreased significantly in the
VLPDþKA group during the follow-up. Protein intake
estimated by PNA was approximately 28% higher than that
calculated by dietary diaries in both groups at baseline.
During the follow-up, PNA did not change in the LPD group
and decreased significantly in the VLPDþKA group. Energy
intake was lower considering the recommendation and did
not change in both groups throughout the entire observa-
tion period.
Phosphorus intake decreased significantly only in the
VLPDþKA group. Calcium intake was low and did not
change during the 4-month study period in both groups. In
the VLPDþKA group, the calcium salts of the ketoacids lead
to a significant increase in total calcium intake.
Table 4 shows the biochemical parameters of the two
groups at baseline and after 4 months. There was no change
in creatinine clearance in both groups during the follow up,
although a trend for a reduction was observed in the LPD
group. Serum creatinine, albumin and bicarbonate were not
modified in either group throughout the follow-up. Serum
urea nitrogen decreased markedly in the VLPDþKA group,
but not significantly in the LPD group. In fact, serum urea
nitrogen decreased in 11 patients (92%) in the VLPDþKA
group and in only six patients (50%) in the LPD group
(Po0.07). Total serum cholesterol and serum glucose were
within the normal range in both groups and did not change
during the 4-month study period. Serum triglycerides was
above the normal range in the LPD group and did not
change during the follow-up. Although not significant, a
tendency to increasing serum triglycerides was observed in
the VLPDþKA. Urinary phosphorus decreased significantly
in the VLPDþKA group and did not change in LPD group
during the follow-up (Figure 2a). Urinary phosphorus
decreased in all patients in the VLPDþKA group contrasting
Table 2 Characteristics of the two groups at baseline
VLPDþ KA (n¼12) LPD (n¼12) P
Sex (M/F) 7/5 8/4
Age (y) 49.7711.3 43.9716.3 0.32
Serum creatinine (mg/dl) 4.671.6 4.971.8 0.63
Creatinine clearance (ml/min) 16.775.3 17.872.9 0.51
Serum Urea Nitrogen (mg/dl) 61.4712.8 61.7723.8 0.96
Urinary protein (g/24 h) 1.2571.5 0.6670.5 0.23
Values given as mean7s.d.
VLPDþKA¼ very-low-protein diet supplemented with ketoacids; LPD¼ low-
protein diet; CKD¼ chronic kidney disease.
Table 3 Anthropometric and dietary parameters during the follow-up
Parameter Baseline 2 months 4 months
VLPDþ KA group
BMI (kg/m2) 24.772.9 24.872.8 24.672.7
Body fat (%)a 23.5710.1 23.579.8 22.079.3
TSF (%) 97.3744.8 101.8744.9 103.4741.1
MAMC (%) 94.6711.6 95.2712.1 93.0711.0
Lean body mass (kg)a 50.9712.5 50.6712.1 51.2712.5
Protein intake (g/kg/day)b 0.6870.17 0.3970.09 0.4370.12*
PNA (g/kg/day) 0.9170.24 0.6970.22 0.6670.11*
Energy intake (kJ/kg/day)b 98.8726.8 97.1725.9 95.8729.3
Energy intake (kcal/ kg/day) 23.676.4 23.276.2 22.977.0
Dietary phosphorus (mg/
day)b
5297109 3717155 3737125*
Dietary Ca (mg/day)b 2947145 208786 2377136
Dietary Caþ ketosteril Ca
(mg/day)b
2947145 8137136 8427163*
LPD group
BMI (kg/m2) 25.574.8 25.774.9 25.874.8
Body fat (%) 25.7711,8 26.7712,4 25.7711.9
TSF (%) 97.7747.9 102.5749.4 105.7749.6**
MAMC (%) 94.4710.6 94.6710.6 96.277.4
Lean body mass (kg) 50.0711.5 48.0713.6 50.5711.7
Protein intake (g/kg/day) 0.6870.19 0.7470.35 0.6970.18
PNA (g/kg/day)a 0.9470.19 0.9670.26 0.8470.12
Energy intake (kJ/kg/day) 95.8732.6 101.3742.3 100.5728
Energy intake (kcal/kg/day) 22.977.8 24.2710.1 24.076.7
Dietary phosphorus (mg/day) 5387175 6037355 5277172
Dietary calcium (mg/day) 312782 2647105 2707124
Values given as mean7s.d.
an¼11.
bn¼10.
*Po0.05 baseline vs 2 months and 4 months; **Po0.05 baseline vs 4 months.
PNA¼ equivalent of protein nitrogen appearance; TSF¼ triceps skinfold
thickness; MAMC¼midarm-muscle circumference; VLPDþKA¼ very-low-
protein diet supplemented with ketoacids; LPD¼ low-protein diet.
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with only five (45%) in the LPD group (P¼0.01). Serum
calcium did not change during the entire observation period
in both groups; however, in the LPD group a tendency for
decreasing serum calcium was observed (Figure 2b). Serum
calcium increased in six patients (54%) in the VLPDþKA
group against only two patients (17%) in the LPD group
(P¼0.89). Serum phosphorus did not change in the LPD
group but tended to decrease in the VLPDþKA group
(Figure 2c). PTH concentration did not change during the
4-month study period in the VLPDþKA group; however, it
increased significantly in the LPD group (Figure 2d). In fact,
PTH concentration increased in 10 patients (83%) in the LPD
group compared to only three patients (30%) in the
VLPDþKA group (Po0.03). Moreover, PTH concentration
decreased in seven patients (70%) in the VLPDþKA group
and only in two patients (17%) in the LPD group (Po0.03).
Comparison between changes of the two groups during
the follow-up
As can be seen in Table 5, significant differences in the
changes from baseline to 4 months were observed when
comparing VLPDþKA and LPD group in the following
parameters: protein intake, dietary phosphorus, dietary
calcium, serum urea nitrogen, serum bicarbonate and
urinary phosphorus.
In the LPD group, the change in PTH concentration was
negatively correlated with changes of ionized calcium
concentration (r¼0.75, P¼0.02) and positively correlated
with changes in serum phosphorus (r¼ 0.71, P¼0.03).
Similar correlations were not observed in the VLPDþKA
group.
Discussion
In the present study, we demonstrated that a VLPDþKA is
safe to maintain the nutritional status of CKD patients at
least during a 4-month period. In fact, the nutritional
parameters, whether anthropometric or biochemical, were
similarly preserved in both groups, even considering the
important food restriction of a VLPDþKA. Our results are in
accordance with previous studies using VLPDþKA for longer
periods of time (Mitch et al, 1982; Walser, 1993; Masud et al,
1994; Tom et al, 1995). Indeed, isotopic studies that
evaluated protein metabolism showed that for both short-
term and long-term treatment periods, neutral or positive
nitrogen balance is attained in patients receiving a
VLPDþKA, yet energy intake was below the recommended
146 kJ/kg/day (35 kcal/kg/day) (Masud et al, 1994; Tom et al,
1995). Similar results regarding low energy intake and
maintenance of nutritional parameters were also observed
in the present study. Some possibilities can be raised to
explain this apparent discrepancy. The first is that the energy
requirements of these patients might be lower than the
recommendation. In fact, Passey et al (2003) measuring the
total energy expenditure and the dietary intake of predialysis
patients following a conventional low protein diet found the
majority of patients would meet their energy expenditure at
126 kJ/kg/day (30 kcal/kg/day) rather than the recommended
146 kJ/kg/day (35 kcal/kg/day). Moreover, some evidence for
lower resting energy expenditure compared to healthy
subjects has been recently demonstrated (O’Sullivan et al,
2002; Avesani et al, 2003). Additionally, in our study the
maintenance of the nutritional status even with low energy
intake could be the result of a higher protein intake as
demonstrated by PNA. Underestimation of energy intake is
another possibility to explain the discrepancy observed in
this study. In fact, studies using doubly labeled water to
measure total energy expenditure in other populations have
demonstrated approximately 20% underestimation in en-
ergy intake when food records were used (Martin et al, 1996;
Kroke et al, 1999). No study using this method of energy
expenditure measurement has been performed in CKD
patients. However, in a study comprising 24 CKD diabetic
patients and 24 CKD nondiabetic patients, the resting energy
expenditure (64387963 and 560571318 kJ/day (15387230
and 13397315 kcal/day), respectively) was very similar to
the energy intake estimated by 4-day food records
(608671515 and 611671754 kJ/day (14547362 and
Table 4 Biochemical parameters at baseline and 4 months
Parameter Baseline 4 months P
VLPDþ KA group
Serum creatinine (mg/dl) 4.671.6 4.671.8 0.84
Creatinine clearance (ml/min) 16.775.3 15.876.4 0.43
Serum urea nitrogen (mg/dl) 61.4712.8 43.6714.9 0.001
Serum albumin (g/dl)a 4.170.4 4.170.45 0.53
Serum bicarbonate (mmol/l)b 25.972.7 24.874.0 0.32
Serum cholesterol (mg/dl) 198742.7 205764.9 0.71
Serum triglycerides (mg/dl) 137759.2 163768.8 0.07
Serum glucose (mg/dl) 97713.2 91716.2 0.19
Ionized calcium (mmol/l)a 1.2170.15 1.2270.17 0.85
Serum phosphorus (mg/dl)a 4.670.5 4.071.1 0.07
Urinary phosphorus (mg/24 h)a 4737164 2407124 0.001
Intact PTH (pg/ml)b 3747222 4337441 0.57
LPD group
Serum creatinine (mg/dl) 4.971.8 4.971.5 0.90
Creatinine clearance (ml/min) 17.872.9 16.173.6 0.05
Serum urea nitrogen (mg/dl) 61.7723.8 56.8718.2 0.21
Serum albumin (g/dl)b 4.370.3 4.370.4 0.94
Serum bicarbonate (mmol/l)a 23.374.0 25.074.3 0.18
Serum cholesterol (mg/dl) 192754.4 205745.4 0.42
Serum triglycerides (mg/dl) 173788.6 1777105.3 0.80
Serum glucose (mg/dl) 96713.4 94713.1 0.74
Ionized calcium (mmol/l) 1.3170.05 1.2670.07 0.05
Serum phosphorus (mg/dl) 4.670.9 4.671.4 0.90
Urinary phosphorus (mg/24 h)a 4427117 4407124 0.91
Intact PTH (pg/ml) 2417138 4947390 0.01
Values given as mean7s.d.
an¼11.
bn¼ 10.
VLPDþKA¼ very-low-protein diet supplemented with ketoacids; LPD¼ low-
protein diet.
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14617419 kcal/day), respectively). As the body mass index
was indicative of overweight (26.874.7 and 25.873.8 kg/m2,
respectively), this result suggests some degree of under-
estimation of energy intake (Avesani et al, 2001). Protein
intake was indeed underestimated in the present study. In
fact, we found that the protein intake estimated by food
records was approximately 28% lower than that calculated
by PNA in both groups during the entire study period. Taking
into account the difference observed between these two
methods, it is evident that the compliance of our patients
was not good, even considering the significant decrease in
protein intake in the VLPDþKA group. It should be
mentioned that our patients were in a clinically stable
condition during the survey period, which excludes the
possibility of the higher PNA being due to a catabolic state.
Similar results were found by Bernhard et al (2001) who
observed a protein intake estimated by food records 22%
lower than that calculated by PNA. Other studies have also
pointed out difficulties with compliance to very low protein
diets even when individualized and intensive counseling are
performed (Forget et al, 1990; Kopple et al, 1997). Compli-
ance is a complex and incompletely understood behavioral
process that is strongly influenced by the environment in
which people live and the social and cultural aspects of the
individual life (Vitolino et al, 2000). In the present study,
although we have not evaluated the causes of the poor
compliance of patients on the VLPDþKA diet, it is likely
that the difficulties were related to the restriction of animal
protein origin, mainly meats, and to the increased intake of
foods rich in vegetable proteins such as beans and bread as
these foods are part of our population food habits. Addi-
tionally, the limitation of food choices could also have
contributed.
One advantage of using VLPDþKA is the reduction in
serum urea nitrogen as demonstrated in many studies
(Forget et al, 1990; Malvy et al, 1999; Aparicio et al, 2000).
In fact, a 28.9% of decrease in this biochemical marker was
found in our study contrasting with only 7.9% in the LPD
group. Although the present study did not aim to compare
the differences in the glomerular filtration rate with both
diets, a tendency was observed for decreasing creatinine
clearance in the LPD group, but not in the VLPDþKA group.
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Figure 2 Individual values of urinary phosphorus (a), ionized calcium (b), serum phosphorus (c) and parathyroid hormone (d) in the baseline
(B) an after 4 months (4M) of follow-up in the VLPDþKA and in LPD.
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Similar results were found in the Modification of Diet in
Renal Disease (MDRD) study B using a more adequate
method to evaluate the glomerular filtration rate (clearance
of I-iothalamate) (Klahr et al, 1994).
The elevated levels of triglycerides observed in the LPD
group is a common finding in patients suffering from
chronic renal failure. The tendency of increasing serum
triglycerides observed in the VLPDþKA group may be due to
the increase in carbohydrate intake to counterbalance the
reduction in protein intake.
The most significant finding from our study is related to
the differences observed in calcium and phosphorus meta-
bolism when comparing the two groups of diet. In contrast
to the LPD group, in the VLPDþKA group the significant
reduction in phosphorus intake with a consequent decrease
in urinary phosphorus may have contributed to the
tendency of a reduction in serum phosphorus. Moreover,
the calcium salts of the ketoacids may have acted as
intestinal phosphate binder. Indeed, a previous study
showed that ketoacids bind phosphorus in vitro as well in
vivo (Schaefer et al, 1989). Our result is in accordance with
other studies that also found a reduction of serum phos-
phorus concentration in patients following a VLPDþKA
(Combe et al, 1995; Barsotti et al, 1998). Serum calcium
remained unchanged in both groups but a tendency to
decrease was observed in the LPD group possibly as a
consequence of a reduction in renal function evaluated by
creatinine clearance and/or by the low calcium intake. On
the other hand, in the VLPDþKA group the calcium salt
supplementation and the preservation of renal function may
have contributed to the maintenance of serum calcium
which, associated with a reduction in serum phosphorus,
may have resulted in the maintenance of serum PTH, while
the reduction of ionized calcium in the LPD group may have
contributed to the increase in the concentration of PTH. In
fact, the change in PTH concentration was negatively
correlated with changes of ionized calcium concentration
in this group. The benefits in calcium and phosphorus
metabolism observed in the VLPDþKA group may have
implications in the treatment of hyperparathyroidism.
Lindenau et al (1990) and Aparicio et al (1992) demonstrated
that patients with advanced renal failure following a
VLPDþKA presented important improvement in bone
histological changes related to hyperparathyroidism. It is
already well demonstrated that a VLPDþKA is effective in
lowering serum PTH levels (Lafage et al, 1992; Combe et al,
1995; Barsotti et al, 1998). Indeed, our results demonstrated a
reduction in the PTH concentration among 70% of the
patients following a VLPDþKA.
In summary, this study indicates that a VLPD supplemen-
ted with ketoacids can maintain the nutritional status of the
patients over a period of 4 months similarly to a conven-
tional LPD. Moreover, an advantage in calcium and phos-
phorus metabolism and serum urea nitrogen reduction in
the ketoacid group over LPD group was also demonstrated.
Thus, VLPDþKA can constitute another therapeutic alter-
native in the treatment of CKD patients.
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